MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
29.89
-1.19
-3.83%
After Hours: 30.00 +0.11 +0.37% 19:43 12/26 EST
OPEN
30.62
PREV CLOSE
31.08
HIGH
30.94
LOW
28.93
VOLUME
965.08K
TURNOVER
--
52 WEEK HIGH
31.18
52 WEEK LOW
1.920
MARKET CAP
1.82B
P/E (TTM)
-7.2568
1D
5D
1M
3M
1Y
5Y
1D
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
Benzinga · 4d ago
U.S. RESEARCH ROUNDUP-APi Group, Elf Beauty, Tesla
Reuters · 6d ago
KODIAK SCIENCES INC <KOD.O>: JEFFERIES RAISES TARGET PRICE TO $39 FROM $24
Reuters · 6d ago
Weekly Report: what happened at KOD last week (1215-1219)?
Weekly Report · 12/22 10:06
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength
NASDAQ · 12/22 04:20
Major Insider Move Signals Bold Confidence in Kodiak Sciences Stock
TipRanks · 12/20 02:05
Felix J. Baker, Director, Reports Acquisition of Kodiak Sciences Inc. Common Shares
Reuters · 12/19 21:07
*Kodiak Sciences Announces Closing of $184M Public Offering of Common Stock >KOD
Dow Jones · 12/19 02:08
More
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.